Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endocrine Response in Women With Invasive Lobular Breast Cancer
NCT02206984Phase 2Completed
- Start
- Sep 2015
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fulvestrant in breast cancer (3 arms). Primary endpoint: Change in Log-transformed Ki67 Proliferative Index. Started Sep 2015; status: completed.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02206984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02206984.